


Cisd2 agonist 2

Cat. No.:	HY-155539		
CAS No.:	2916371-59-8		
Molecular Formula:	C ₁₄ H ₁₄ N ₂ O ₄ S		
Molecular Weight:	306.34		
Target:	Others		
Pathway:	Others		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (326.43 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	3.2643 mL	16.3217 mL	32.6435 mL
		5 mM	0.6529 mL	3.2643 mL	6.5287 mL
10 mM		0.3264 mL	1.6322 mL	3.2643 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.5 mg/mL (8.16 mM); Clear solution; Need ultrasonic Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (8.16 mM); Clear solution; Need ultrasonic Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: 2.5 mg/mL (8.16 mM); Clear solution; Need ultrasonic 				

BIOLOGICAL ACTIVITY

Description	Cisd2 agonist 2 (compound 6) is an orally active Cisd2 activator (EC ₅₀ =191 nM), while the Cisd2 levels is correlated with nonalcoholic fatty liver disease (NAFLD). Cisd2 agonist 2 has no significant toxicity in vivo in Cisd2hKO-het mice (heterozygous hepatocyte-specific Cisd2 knockout) ^[1] .
IC₅₀ & Target	CDGSH iron sulfur domain-containing 2 (Cisd2) ^[1]

REFERENCES

[1]. Yao CH, et al. Discovery of tetrasubstituted thiophenes as Cisd2 activators: A potential novel therapeutic option in nonalcoholic fatty liver disease. Eur J Med Chem. 2023 Oct 5;258:115583.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA